Navigation Links
P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth
Date:10/29/2008

nation of pricing and product mix is expected to impact sales growth by a positive two to three percent. Foreign exchange is expected to have a negative impact of one to two percent. The net impact of acquisitions and divestitures is estimated to lower net sales by one to two percent. Total sales are expected to increase one to three percent. This is a decrease of four percent versus the company's previous guidance range due to foreign exchange.

The Company also widened its earnings per share outlook range to $4.15 to $4.25. This maintains the high end of the Company's previous outlook, but recognizes the continued volatility in commodity and energy markets and increasing volatile foreign exchange markets. The company's outlook includes an estimated $0.50 per share of gain from the Folgers transaction and about $0.12 per share of incremental restructuring charges. Operating margin and tax rate guidance was unchanged.

For the October - December quarter, organic sales are expected to grow four to six percent. The combination of pricing and product mix is expected to contribute about four percent to sales growth. Foreign exchange is expected to have a negative impact of two to three percent. The net impact of acquisitions and divestitures is estimated to have a negative two percent impact on sales growth. Total sales are expected to be negative one to positive two percent.

The Company expects earnings per share to be in the range of $1.45 to $1.50 for the quarter, including the estimated $0.50 per share of Folgers gain and $0.03 per share of additional Folgers-related restructuring charges. Operating margin is expected to decline modestly as overhead productivity improvements will be more than offset by lower gross margins.

Forward Looking Statements

All statements, other than statements of historical fact included in this release, are forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act
'/>"/>

SOURCE The Procter & Gamble Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Cardinal Health Reports First Quarter Results
2. uKarma Reports Progress With International Distribution Agreement for Its Xflowsion DVD Series
3. STAAR Surgical Reports 33% Third Quarter Revenue Growth
4. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
5. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
6. LCA-Vision Reports Third Quarter 2008 Financial Results
7. Universal Health Services, Inc. Reports 2008 Third Quarter Results
8. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
9. Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009
10. WellPoint Reports Third Quarter 2008 Results
11. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... OH, July 10, 2014 -- The World Health Organization ... minutes of moderate to vigorous physical activity (MVPA) each ... of their MVPA during school hours. Therefore, it ... hours would increase MVPA. In a new study ... , researchers confirmed that time spent outdoors after school ...
(Date:7/9/2014)... TORONTO, July 10, 2014 For the first time, ... urban Aboriginal population in Canada uses health care. A ... database to clearly demonstrate the unique challenges faced by ... at St. Michael,s Hospital. , The findings, published ... between urban First Nations individuals and the general population. ...
(Date:7/9/2014)... the Perelman School of Medicine at the University of ... have received an $8 million grant from the National ... light therapy (PDT) in patients with malignant pleural mesothelioma, ... manifests itself in the lining of the lungs and ... grant will fund a clinical trial and additional studies ...
(Date:7/9/2014)... A network of signals active in almost all types ... into overdrive, and may help fuel a tumour,s uncontrolled ... of Cancer Research, London, identified a molecular trigger responsible ... the cellular factory that makes the building blocks ... in the TOR signalling pathway, called SREBP, controls the ...
(Date:7/9/2014)... Studying the most common type of lung cancer, researchers ... a role in forming tumors. The new knowledge may ... these genetic changes already are available or are in ... , investigators from The Cancer Genome Atlas (TCGA), including ... Louis, Harvard Medical School and other institutions, studied tumors ...
Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2
... Reporter , MONDAY, Feb. 28 (HealthDay News) -- The battle of ... players in the fight to reduce waistlines, two new studies report. ... told by their doctors that they are overweight or obese, they ... likely to want to lose weight and to try to lose ...
... State University School of Medicine physician-researcher has developed a ... The treatment is based on a naturally occurring human ... cells into killing themselves. The unique concept, patented ... cells that are resistant to routine treatments such as ...
... Feb. 28, 2011 Los Angeles Biomedical Research ... Inc., a Japanese biotechnology firm, have entered into a ... in regenerative medicine, "Cell Sheet Engineering," LA BioMed President ... "LA BioMed is working to accelerate the pace of ...
... , A new University of Colorado Boulder study indicates ... in helping to treat people with mild traumatic brain ... U.S. war veterans returning home. The study involved ... are used to stimulate particular points on a person,s ...
... (BUSM) have found that patients with node negative T3 ... surgery had more than three times the survival rate ... appear on-line in the Journal of Thoracic and ... total of 110 patients who underwent surgical resection for ...
... brain imaging study at the U.S. Department of Energy,s (DOE) ... subjects and those who compulsively overeat, or binge: In binge ... smell of favorite foods triggers a spike in dopamine - ... - published online on February 24, 2011, in the journal ...
Cached Medicine News:Health News:Doctors Can Influence Patients to Lose Weight: Studies 2Health News:Doctors Can Influence Patients to Lose Weight: Studies 3Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 2Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 3Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 4Health News:LA BioMed and CellSeed to launch joint research project on regenerative medicine technology 2Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 2Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 3Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 4Health News:Binge eaters' dopamine levels spike at sight, smell of food 2Health News:Binge eaters' dopamine levels spike at sight, smell of food 3
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... January 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender offer ...   As a result of the waiver, the transaction ... complete the tender offer on January 24, 2014 following the currently ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Data Provides Ophthalmologists Critical Insight on Novel Beta ... Radiation Epiretinal Therapy, ... a one-year feasibility study of the company,s novel beta,radiation epiretinal therapy ... Annual Meeting of the American Academy of,Ophthalmology in New Orleans, Louisiana. ...
... American College of Rheumatology Annual Congress -, ... BMY ) today announced the results of three ... showed ORENCIA(R) (abatacept) improved daily,activity participation, such as ... sleep quality in adult rheumatoid arthritis,(RA) patients who ...
Cached Medicine Technology:NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO 2NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO 3Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 2Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 3Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 4Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 5Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 6Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 7Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 8Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 9
... a single use rapid test, for the detection ... whole blood (venipuncture). Uni-Gold Recombigen HIV is intended ... an aid in diagnosis of infection with HIV-1. ... multi-test algorithms designed for the statistical validation of ...
... HIV-1 Oral Specimen Collection Device is a safe, ... antibodies. Testing with the OraSure HIV-1 Oral Specimen ... has been shown to be more than 99% ... cotton fiber pad attached to a nylon stick ...
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
... Angle CHS System takes the time proven ... , ,The VHS® Supracondylar Cable Plate is ... distal femur fractures including periprosthetic fractures. The ... variable angle of the barrel and the ...
Medicine Products: